Clinical Trial: An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Patients With Myeloid Malignancies

U.S., June 2 -- ClinicalTrials.gov registry received information related to the study (NCT07619287) titled 'An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Patients With Myeloid Malignancies' on May 22.

Brief Summary: The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of BG-75202 (KAT6A/B inhibitor) alone and in combination with other agents in patients with myeloid malignancies.

Study Start Date: June 01

Study Type: INTERVENTIONAL

Condition: Myeloid Malignancy

Intervention: DRUG: BG-75202

Administered orally

DRUG: Hypomethylation Agent (HMA)

Administered Intravenous (IV) or Subcutaneous (SC)

Recruitment Status: NO...